Literature DB >> 10950847

Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine.

J S Ngui1, W Tang, R A Stearns, M Shou, R R Miller, Y Zhang, J H Lin, T A Baillie.   

Abstract

The metabolism of diclofenac to its 5-hydroxylated derivative in humans is catalyzed by cytochrome P450 (CYP)3A4. We report herein that in vitro this biotransformation pathway is stimulated by quinidine. When diclofenac was incubated with human liver microsomes in the presence of quinidine, the formation of 5-hydroxydiclofenac increased approximately 6-fold relative to controls. Similar phenomena were observed with diastereoisomers of quinidine, including quinine and the threo epimers, which produced an enhancement in the formation of 5-hydroxydiclofenac in the order of 6- to 9-fold. This stimulation of diclofenac metabolism was diminished when human liver microsomes were pretreated with a monoclonal inhibitory antibody against CYP3A4. In contrast, neither cytochrome b(5) nor CYP oxidoreductase appeared to mediate the stimulation of diclofenac metabolism by quinidine, suggesting that the effect of quinidine is mediated through CYP3A4 protein. Further kinetic analyses indicated that V(max) values for the conversion of diclofenac to its 5-hydroxy derivative increased 4.5-fold from 13.2 to 57.6 nmol/min/nmol of CYP with little change in K(m) (71-56 microM) over a quinidine concentration range of 0 to 30 microM. Conversely, the metabolism of quinidine was not affected by the presence of diclofenac; the K(m) value estimated for the formation of 3-hydroxyquinidine was approximately 1.5 microM, similar to the quinidine concentration required to produce 50% of the maximum stimulatory effect on diclofenac metabolism. It appears that the enhancement of diclofenac metabolism does not interfere with quinidine's access to the ferriheme-oxygen complex, implicating the presence of both compounds in the active site of CYP3A4 at the same time. Finally, a approximately 4-fold increase in 5-hydroxydiclofenac formation was observed in human hepatocyte suspensions containing diclofenac and quinidine, demonstrating that this type of drug-drug interaction occurs in intact cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950847

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

Review 2.  Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?

Authors:  Dmitri R Davydov; James R Halpert
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-12       Impact factor: 4.481

3.  Pivotal role of P450-P450 interactions in CYP3A4 allostery: the case of α-naphthoflavone.

Authors:  Dmitri R Davydov; Nadezhda Y Davydova; Elena V Sineva; Irina Kufareva; James R Halpert
Journal:  Biochem J       Date:  2013-07-15       Impact factor: 3.857

4.  Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.

Authors:  Anna L Blobaum; Thomas M Bridges; Frank W Byers; Mark L Turlington; Margrith E Mattmann; Ryan D Morrison; Claire Mackie; Hilde Lavreysen; José M Bartolomé; Gregor J Macdonald; Thomas Steckler; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2013-09-03       Impact factor: 3.922

5.  An in vitro system for measuring genotoxicity mediated by human CYP3A4 in Saccharomyces cerevisiae.

Authors:  Michael Fasullo; Julian Freedland; Nicholas St John; Cinzia Cera; Patricia Egner; Matthew Hartog; Xinxin Ding
Journal:  Environ Mol Mutagen       Date:  2017-04-24       Impact factor: 3.216

6.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

7.  Rapid LC-MS drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format.

Authors:  Besnik Bajrami; Linlin Zhao; John B Schenkman; James F Rusling
Journal:  Anal Chem       Date:  2009-12-15       Impact factor: 6.986

8.  Effect of glutathione on homo- and heterotropic cooperativity in cytochrome P450 3A4.

Authors:  Dmitri R Davydov; Nadezhda Y Davydova; Tamara N Tsalkova; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2008-01-11       Impact factor: 4.013

9.  Quinidine in the treatment of KCNT1-positive epilepsies.

Authors:  Mohamad A Mikati; Yong-Hui Jiang; Michael Carboni; Vandana Shashi; Slave Petrovski; Rebecca Spillmann; Carol J Milligan; Melody Li; Annette Grefe; Allyn McConkie; Samuel Berkovic; Ingrid Scheffer; Saul Mullen; Melanie Bonner; Steven Petrou; David Goldstein
Journal:  Ann Neurol       Date:  2015-11-18       Impact factor: 10.422

10.  Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions.

Authors:  Avanthika Venkatachalam; Abhinav Parashar; Kelath Murali Manoj
Journal:  In Silico Pharmacol       Date:  2016-02-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.